Across TCGA pan-cancer cohorts, ADGRA1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ADGRA1 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ADGRA1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADGRA1 expression acts as an unfavorable survival marker.
HNSC, LIHC, and ACC are the cancer types where ADGRA1 Mutation most reproducibly stratifies survival.